Dr. Chapa’s OBGYN Clinical Pearls

Dr. Chapa’s Clinical Pearls
undefined
Jul 12, 2020 • 13min

Tamoxifen for Nexplanon Bleeding? A New RCT.

LARCS are endorsed by the ACOG due to the high efficacy. However, unpredictable bleeding can affect continuation rates. A new RCT has evaluated the use of tamoxifen to control and prevent future abnormal bleeding with etonogestrel implant use. Does this work? What is the MOA? In this session, we will summarize this new publication (published ahead of print) in Obstetrics and Gynecology.
undefined
Jul 10, 2020 • 9min

Cesarean’s AMAZING History (Part 2)

Did you know that silver wire helped to dramatically reduce maternal mortality at cesarean section? And what does the Goodyear Rubber Company have to do with surgical techniques? In this episode we will wrap up our walk through history reviewing CS’s AMAZING History.
undefined
Jul 9, 2020 • 17min

Cesarean’s AMAZING History (Part 1)

What does a pig gelder, a woman dressed as a man, and the Queen of England all have in common? The answer: ALL CONTRIBUTED TO CS’s history! The history of C-section has been called the combination of “death, deceit, and germs“. In this historical review (Part 1), we will take a look at the origin of this all too frequent abdominal surgery.
undefined
Jul 5, 2020 • 11min

Pregnant & Prone for Resp Support

Prone positioning during invasive mechanical ventilation improves oxygenation, as shown in large randomized clinical trials of patients with ARDS. In an RCT that included 466 patients with moderate and severe ARDS, prone positioning for at least 16 hours per day with protective mechanical ventilation reduced 90-day mortality. Is prone positioning for respiratory support possible in pregnancy? In this session we will cover the beneficial effect of probe positioning and summarize an article (EPUB) soon to be in print in Obstetrics & Gynecology regarding prone therapy in pregnancy (Tolcher et al).
undefined
Jul 2, 2020 • 14min

Fetal Gastroschisis.

Gastroschisis occurs in about 1 in 1800 births in the US. Does this abdominal wall herniation usually occur to the right or left of the umbilical cord? Is this condition tied to chromosomal/genetic syndrome? What about antepartum fetal surveillance? Is a cesarean birth required? In this episode, we will review the SMFM and CDC data regarding management of gastroschisis.
undefined
Jul 2, 2020 • 14min

Female Circumcision: ACOG/WHO Response

Female genital mutilation (FGM) is also known as female circumcision. The ACOG and the World Health Organization have issued public statements condemning the practice. What is this procedure? What are the 4 different types of female genital cutting? In this session we will review these answers as well as the immediate and long-term complications of FGM. We will also review the WHO international response to this unnecessary medical practice.
undefined
Jun 28, 2020 • 6min

Polyhydramnios Part 2: SMFM Review, Intrapartum Care

Is labor affected by polyhydramnios? What is the suggested manner of performing artificial rupture of membranes in this setting? In this session, we will wrap up our discussion of polyhydramnios with a quick summary on intrapartum care.
undefined
Jun 26, 2020 • 15min

Polyhydramnios Part 1 (SMFM #46)

Polyhydramnios can be mild, moderate, or severe. Is deepest vertical pocket (DVP) or AFI preferred for amniotic fluid assessment? Is antepartum Indocin a valid treatment option? What about antepartum fetal surveillance? In this session, which is Part 1, we will review the SMFM guidance regarding polyhydramnios.
undefined
Jun 22, 2020 • 15min

Placenta Accreta Spectrum

Placenta accreta spectrum, formally known as morbidly adherent placenta, refers to a range of pathologic adherence of the placenta (accreta, increta, and percreta). There is significant risk of maternal morbidity and mortality including risk of blood transfusion, life-threatening hemorrhage, and hysterectomy. In this session, we will review the obstetric care consensus by the ACOG and SMFM regarding this condition (obstetric care consensus # 7).
undefined
Jun 20, 2020 • 7min

Oriahnn for Fibroids HMB (New Med Approval)

On May 29, 2020, the U.S. FDA approved an novel oral drug, Oriahnn, for HMB use to fibroids. This medication (elagolix, estradiol, and norethindrone acetate) is the first oral medication designed specifically for Fibroid HMB. In this session, we will review this new medication. (No financial disclosures to report).

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app